/
Unless the context otherwise requires, we , us , and our , the Company and PAVmed refer to PAVmed Inc. and its subsidiaries, including its subsidiary Lucid Diagnostics Inc. (Nasdaq:LUCD) ( Lucid Diagnostics or Lucid ) and its majority-owned subsidiary Veris Health Inc. ( Veris Health or Veris ). Background and Overview PAVmed is a diversified commercial-stage life sciences company operating in …
$5.93
$0.09 (-1.58%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-30712.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 97.6% YoY. Margins deteriorated 29229.8pp alongside, both lines moving the wrong way.
Negative free cash flow of -$5M. The business is consuming cash, not generating it. Operating margin contracted 29229.8pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$85K
▼ -97.6% YoY
Net Income (TTM)
-$19M
▼ -99.0% YoY
Op. Margin
-28700.00%
▼ -29229.8pp YoY
ROIC
-45.97%
▲ +876.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +84.4% YoY
Op. Cash Flow (TTM)
-$6M
▲ +84.5% YoY
Net Debt
$11M
Cash & Equiv.
$6M
3Y CAGR: -42.7%
Continue Research
PAVmed (PAVM)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, PAVmed scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
PAVmed scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -28,700.0% operating margin and a -46.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PAVM's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.